WK Kellogg Co (KLG) Q1 2025 earnings summary

Executive summary

• Q1 2025 net sales declined 6.2% year-over-year to $663 million, with organic net sales down 5.6% and net income falling 45% to $18 million due to higher restructuring and separation costs.

• Adjusted EBITDA for Q1 2025 was $72 million, down 4% year-over-year, with adjusted EBITDA margin rising to 10.8%.

• The company is executing a major supply chain modernization, including plant closures and ERP implementation, with cumulative restructuring charges expected to reach $230–$270 million through 2027.

• Strategic priorities focus on supply chain modernization, brand scaling, and health & wellness innovation, targeting ~500 bps margin improvement by end of 2026.

• U.S. and Canada market share and sales declined, with U.S. sales down 4.5% and Canada down 5.5% year-over-year.

Financial highlights

• Q1 2025 reported net sales: $663M (down 6.2%); organic net sales: $667M (down 5.6%).

• Adjusted EBITDA: $72M (down 4.0% year-over-year); adjusted EBITDA margin: 10.8% (up 20 bps year-over-year).

• Adjusted gross margin: 29.4% (up 20 bps year-over-year); reported gross profit margin: 28.5% (down 20 bps).

• Free cash flow for Q1 2025 was negative $62M, with net cash flow from operations at ($2M).

• Net debt at quarter end was $570M, with a leverage ratio of 2.1x.

Outlook and guidance

• 2025 organic net sales growth guidance lowered to (2.0)%–(3.0)% from prior ~ (1.0)%.

• 2025 adjusted EBITDA growth guidance reduced to flat to (2.0)% from previous 4.0%–6.0%.

• Management expects continued cost pressures from macroeconomic and regulatory factors, including potential new tariffs and FDA color additive regulations.

• Sequential improvement in performance is expected each quarter into the back half of the year, driven by distribution gains and strategic investment allocation.

• 500 basis points of EBITDA margin expansion by end of 2026 reiterated, primarily through gross margin improvements.